Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas

NCT02055924 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

85

Enrollment

OTHER

Sponsor class

Stopped ANSM decision due to veino occlusive disease (security alert)

Conditions

B-cell Lymphoma

Interventions

DRUG: Ibrutinib and immunochemotherapies

Sponsor

The Lymphoma Academic Research Organisation

Collaborators

[object Object]